Test Price
2,800 AED✅ Home Collection Available
ATL1 Gene (SPG3A) Next‑Generation Sequencing (NGS) Genetic Test | UAE | AED 2,800
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited next‑generation sequencing processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post‑test interpretation and genetic counselling support.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ATL1 Gene (SPG3A) Next‑Generation Sequencing (NGS) Genetic Test detects pathogenic variants in the ATL1 gene, which is the primary cause of autosomal dominant hereditary spastic paraplegia type 3A (SPG3A). Using high‑throughput NGS on the Illumina® platform with advanced bioinformatic variant calling, the test delivers comprehensive coverage of all coding and deep intronic regions, enabling detection of both common and rare mutations that Sanger sequencing may miss.
| Feature | Our Test (ATL1 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | >99.9% sensitivity for all ATL1 variants, including deep intronic regions (NGS breadth) | Targeted analysis of known hotspots; may miss rare or novel mutations |
| Methodology | Next‑Generation Sequencing (NGS) with Illumina® platform & bioinformatic variant calling | Sanger sequencing, limited to single‑amplicon interrogation |
| Turnaround Time | 3 to 4 weeks | 2 to 3 weeks |
Physician Insight & Safety Protocols
“This NGS‑based analysis of the ATL1 gene provides comprehensive detection of pathogenic variants responsible for hereditary spastic paraplegia type 3A. A positive result must always be correlated with a detailed neurological examination and family history — it does not independently predict disease onset or severity. I strongly recommend post‑test genetic counselling and a multidisciplinary neurological care plan for all patients.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
⚠️ Important Safety Notice
Do not discontinue or alter any prescribed medication without consulting your treating physician. This genetic test is a diagnostic aid and is not a substitute for ongoing neurological care or emergency treatment.
Exclusion Criteria & Emergency Red Flags
Patient Selection & Urgent Referral
- Exclusion: Individuals under 18 years of age without legal guardian consent; patients unable to provide informed consent for genetic testing.
- Emergency Red Flag: Acute, rapid loss of ambulation, new‑onset bowel or bladder dysfunction, or severe worsening of spasticity within hours — seek emergency care immediately.
- Post‑test Guidance: A positive result alone does not constitute a medical emergency, but prompt neurology follow‑up and genetic counselling are essential.
Patient FAQ & Clinical Guidance
1. What is the ATL1 Gene (SPG3A) Test used for?
This test confirms a diagnosis of hereditary spastic paraplegia type 3A by identifying disease‑causing variants in the ATL1 gene. Results guide clinical management, treatment decisions, and family planning through cascade testing of at‑risk relatives.
2. How is the test performed and what is the turnaround time?
A standard peripheral whole‑blood sample, extracted DNA, or a dried blood spot on a DNA FTA card is collected via VIP Mobile Phlebotomy or at our Dubai Healthcare City facility. Laboratory processing using NGS takes 3 to 4 weeks from sample receipt.
3. What do positive results mean and what are the next steps?
A positive result identifies a pathogenic ATL1 mutation, confirming SPG3A. Immediate next steps include a neurology consultation, post‑test genetic counselling, and family cascade testing when indicated. A negative result does not completely rule out hereditary spastic paraplegia, and clinical correlation is essential.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Governance: DNA Labs UAE operates under the regulatory framework of the Dubai Health Authority (DHA) and complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed solely for diagnostic purposes with explicit patient consent. Clinical safety and patient consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | ATL1 Gene (SPG3A) Next‑Generation Sequencing (NGS) Genetic Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or DNA FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina® platform with bioinformatic variant calling |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 21656-8 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians